+

MA52809A - Inhibiteurs de sarm1 - Google Patents

Inhibiteurs de sarm1

Info

Publication number
MA52809A
MA52809A MA052809A MA52809A MA52809A MA 52809 A MA52809 A MA 52809A MA 052809 A MA052809 A MA 052809A MA 52809 A MA52809 A MA 52809A MA 52809 A MA52809 A MA 52809A
Authority
MA
Morocco
Prior art keywords
sarm1 inhibitors
sarm1
inhibitors
Prior art date
Application number
MA052809A
Other languages
English (en)
Inventor
Jonathan Bentley
Todd Bosanac
Andrew Simon Brearley
Rajesh Devraj
Robert Owen Hughes
Richard Andrew Jarjes-Pike
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of MA52809A publication Critical patent/MA52809A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA052809A 2018-06-07 2019-06-06 Inhibiteurs de sarm1 MA52809A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862682045P 2018-06-07 2018-06-07

Publications (1)

Publication Number Publication Date
MA52809A true MA52809A (fr) 2021-04-14

Family

ID=68770684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052809A MA52809A (fr) 2018-06-07 2019-06-06 Inhibiteurs de sarm1

Country Status (8)

Country Link
US (1) US20220194933A1 (fr)
EP (1) EP3801499B1 (fr)
JP (1) JP7478142B2 (fr)
CN (1) CN112839648B (fr)
CA (1) CA3102598A1 (fr)
ES (1) ES2988933T3 (fr)
MA (1) MA52809A (fr)
WO (1) WO2019236884A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
MA52813A (fr) 2018-06-07 2021-04-14 Disarm Therapeutics Inc Inhibiteurs de sarm1
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US12083114B2 (en) 2018-12-19 2024-09-10 Disarm Therapeutics, Inc. Inhibitors of SARM1 in combination with neuro-protective agents
TW202134436A (zh) * 2019-11-26 2021-09-16 美商達薩瑪治療公司 用於神經保護之方法及組成物
JP7478252B2 (ja) 2020-04-09 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
CA3174320A1 (fr) * 2020-04-09 2021-10-14 Jonathan Bentley Derives de pyrazole condenses utiles en tant qu'inhibiteurs de sarm1
TW202334117A (zh) * 2020-08-24 2023-09-01 美商達薩瑪治療公司 Sarm1之抑制劑
KR20250121164A (ko) * 2022-11-12 2025-08-11 캠브리지 엔터프라이즈 리미티드 치료법 및 화장품에 사용하기 위한 sarm1 제제
WO2024222835A1 (fr) * 2023-04-27 2024-10-31 Sironax Ltd. Modulateurs de sarm1, préparations et leurs utilisations
CN116836162B (zh) * 2023-05-24 2025-09-05 南方医科大学 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA847926B (en) * 1983-10-17 1986-05-28 Lilly Co Eli 3-bicyclicpyridinium-methyl cephalosporins
US5468757A (en) * 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
CA2348734A1 (fr) * 1998-10-30 2000-05-11 Merck & Co., Inc. Inhibiteurs de la thrombine
WO2002083175A1 (fr) * 2001-04-11 2002-10-24 Senju Pharmaceutical Co., Ltd. Agents ameliorant la fonction visuelle
US7557103B2 (en) * 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
WO2009041567A1 (fr) * 2007-09-27 2009-04-02 Banyu Pharmaceutical Co., Ltd. Dérivè de diaryl kétimine à activité antagoniste sur le récepteur de l'hormone de concentration de la mélanine
US8518952B2 (en) * 2008-08-06 2013-08-27 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
CA2780922A1 (fr) * 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC Derives de la 7-aminofuropyridine
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
CA2825599C (fr) * 2011-02-01 2021-07-13 The Board Of Trustees Of The University Of Illinois Composes 4-methyl-n-hydroxybenzamide comme inhibiteurs d'histone deacetylase (hdac)
GB201310460D0 (en) * 2013-06-12 2013-07-24 Lytix Biopharma As Compounds
CN106456605A (zh) * 2014-02-25 2017-02-22 艾其林医药公司 用于治疗补体介导的疾病的氨基化合物
EP3481391A4 (fr) * 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
EP3515426A1 (fr) 2016-09-24 2019-07-31 Washington University Inhibiteurs de l'activité sarm1 nadase et utilisations de ceux-ci
US10323036B2 (en) * 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3801499A4 (fr) 2022-01-12
ES2988933T3 (es) 2024-11-22
WO2019236884A1 (fr) 2019-12-12
EP3801499B1 (fr) 2024-02-28
JP7478142B2 (ja) 2024-05-02
CA3102598A1 (fr) 2019-12-12
JP2021528488A (ja) 2021-10-21
CN112839648B (zh) 2025-04-04
EP3801499A1 (fr) 2021-04-14
US20220194933A1 (en) 2022-06-23
CN112839648A (zh) 2021-05-25

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
IL269196A (en) Novel inhibitors
EP3843714A4 (fr) Inhibiteurs de cd73
MA52812A (fr) Inhibiteurs de sarm1
DK3740479T3 (da) Dna-pk-hæmmere
EP3788042A4 (fr) Inhibiteurs de bcl-2
MA52413A (fr) Inhibiteurs de cd73
EP3846674C0 (fr) Spéculum vaginal
MA53287A (fr) Inhibiteurs de prmt5
MA52635A (fr) Inhibiteurs de magl
DK3571192T3 (da) Jak1-selektive inhibitorer
MA52809A (fr) Inhibiteurs de sarm1
IL304348A (en) Cd73 inhibitors
PT3746446T (pt) Inibidores de prc2
EP3801500A4 (fr) Inhibiteurs de sarm1
EP3817736A4 (fr) Inhibiteurs de pikfyve
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3786157A4 (fr) Inhibiteur de l'interaction protéine-protéine mll1-wdr5 de phényle triazole
EP3805381A4 (fr) Phytase mutée
EP3784463A4 (fr) Fluorosulfones
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP3760247A4 (fr) Séparateur de toxines
EP3706742A4 (fr) Inhibiteurs de prmt5
EP3833664A4 (fr) Inhibiteurs de smad3
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载